P2RY12 and cancer: Despite promising pre-clinical data, the ADP P2Y12 receptor antagonist prasugrel (TRITON-TIMI 38 trial) (281, 282) and the P2Y12 inhibitors thienopyridines (clopidogrel and prasugrel) (283) increased the incidence of newly diagnosed solid cancers and the risk of cancer-related death.